Dynamic changes of the extracellular matrix after acute tako-tsubo cardiomyopathy

Funding Tenovus Scotland. Grant number G13/10.Peer reviewedPublisher PD

The impact of methodological and temporal variation on infarct size quantification in acute myocardial infarction with late enhancement CMR

Funding This project was funded by a grant from the MRC(UK).Peer reviewedPublisher PD

Right Ventricular Involvement and Recovery after Acute Stress-Induced (Tako-tsubo) Cardiomyopathy

Acknowledgment: The authors would like to thank all National Health Service Consultant Colleagues at Aberdeen Royal Infirmary for help with prompt recruitment of these patients (Dr. M Metcalfe, MD, Dr. AD Stewart, MD, Dr. A Hannah, MD, Dr. A Noman, MD, Dr. P Broadhurst, MD, Dr. D Hogg, MD, and Dr. D Garg, MD) and to Dr. Gordon Prescott, PhD for help and advice with the statistical methods. This work was supported by a Tenovus Scotland, Nice, France award to Dr. Dawson and presented in part at the Society for Cardiovascular Magnetic Resonance Imaging/EuroCMR 2015 Joint Scientific Sessions from February 5 2015 to February 7, 2015Peer reviewedPostprin

MOLLI T1 mapping versus T2 W-SPAIR at 3T : myocardial area at risk measurements and the influence of microvascular obstruction

Funding Information: This study was supported by a Medical Research Council (UK) grant, as a sub-study of Nitrites in Acute Myocardial Infarction, NCT01388504.Peer reviewe

Erratum:Randomized double-blind placebo-controlled trial of perhexiline in heart failure with preserved ejection fraction syndrome (Future Cardiology (2014) 10:6 (693-698))

Following publication of the Clinical Trial Protocol by Satnam Singh, Roger Beadle, Donnie Cameron, Amelia Rudd, Maggie Bruce, Baljit Jagpal, Konstantin Schwarz, Gemma Brindley, Fergus McKiddie, Chim Lang, Dana Dawson and Michael Frenneaux, titled ‘Randomized double-blind placebo-controlled trial of perhexiline in heart failure with preserved ejection fraction syndrome’, which appeared in the December 2014 issue of Future Cardiology (Future Oncol. 10[6], 693–698 [2014]), it has been brought to our attention that the author names were presented incorrectly as:Satnam Singh, Roger Beadle, Donnie Cameron, Amelia Rudd, Maggie Bruce, Baljit Jagpal, Konstantin Schwarz, Gemma Brindley, Fergus Mckiddie, Peter Nightingale, Chim Lang, Dana Dawson and Michael Frenneaux.The correct presentation should be:Satnam Singh, Roger Beadle, Donnie Cameron, Amelia Rudd, Maggie Bruce, Baljit Jagpal, Konstantin Schwarz, Gemma Brindley, Fergus Mckiddie, Chim Lang, Dana Dawson and Michael Frenneaux.The authors and editors of Future Cardiology would like to sincerely apologize for any inconvenience or confusion this may have caused our readers.<br/

Erratum:Randomized double-blind placebo-controlled trial of perhexiline in heart failure with preserved ejection fraction syndrome (Future Cardiology (2014) 10:6 (693-698))

Following publication of the Clinical Trial Protocol by Satnam Singh, Roger Beadle, Donnie Cameron, Amelia Rudd, Maggie Bruce, Baljit Jagpal, Konstantin Schwarz, Gemma Brindley, Fergus McKiddie, Chim Lang, Dana Dawson and Michael Frenneaux, titled ‘Randomized double-blind placebo-controlled trial of perhexiline in heart failure with preserved ejection fraction syndrome’, which appeared in the December 2014 issue of Future Cardiology (Future Oncol. 10[6], 693–698 [2014]), it has been brought to our attention that the author names were presented incorrectly as:Satnam Singh, Roger Beadle, Donnie Cameron, Amelia Rudd, Maggie Bruce, Baljit Jagpal, Konstantin Schwarz, Gemma Brindley, Fergus Mckiddie, Peter Nightingale, Chim Lang, Dana Dawson and Michael Frenneaux.The correct presentation should be:Satnam Singh, Roger Beadle, Donnie Cameron, Amelia Rudd, Maggie Bruce, Baljit Jagpal, Konstantin Schwarz, Gemma Brindley, Fergus Mckiddie, Chim Lang, Dana Dawson and Michael Frenneaux.The authors and editors of Future Cardiology would like to sincerely apologize for any inconvenience or confusion this may have caused our readers.<br/

Alterations in Cardiac Deformation, Timing of Contraction and Relaxation, and Early Myocardial Fibrosis Accompany the Apparent Recovery of Acute Stress-Induced (Takotsubo) Cardiomyopathy : An End to the Concept of Transience

This work was supported by grants from Tenovus Scotland and the British Heart Foundation (to Dr. Dawson, G13/10 and PG/15/108/31928, respectively). Dr. Dawson has a research agreement with Philips Healthcare and holds a material transfer agreement with AMAG Pharmaceuticals.Peer reviewedPostprin

Cohort profile for the STratifying Resilience and Depression Longitudinally (STRADL) study:A depression-focused investigation of Generation Scotland, using detailed clinical, cognitive, and neuroimaging assessments

Grant information: STRADL is supported by the Wellcome Trust through a Strategic Award (104036/Z/14/Z). GS:SFHS received core support from the CSO of the Scottish Government Health Directorates (CZD/16/6) and the Scottish Funding Council (HR03006). ADM is supported by Innovate UK, the European Commission, the Scottish Funding Council via the Scottish Imaging Network SINAPSE, and the CSO. HCW is supported by a JMAS SIM Fellowship from the Royal College of Physicians of Edinburgh, by an ESAT College Fellowship from the University of Edinburgh, and has received previous funding from the Sackler Trust. LR has previously received financial support from Pfizer (formerly Wyeth) in relation to imaging studies of people with schizophrenia and bipolar disorder. JDH is supported by the MRC. DJM is an NRS Clinician, funded by the CSO. RMR is supported by the British Heart Foundation. ISP-V and MRM are supported by the NIHR Biomedical Research Centre at the University Hospitals Bristol NHS Foundation Trust and the University of Bristol. The views expressed in this publication are those of the author(s) and not necessarily those of the NHS, the National Institute for Health Research or the Department of Health; and MRM is also supported by the MRC MC_UU_12013/6). JMW is supported by MRC UK Dementia Research Institute and MRC Centre and project grants, EPSRC, Fondation Leducq, Stroke Association, British Heart Foundation, Alzheimer Society, and the European Union H2020 PHC-03-15 SVDs@Target grant agreement (666881). DJP is supported by Wellcome Trust Longitudinal Population Study funding (216767/Z/19/Z) the Eva Lester bequest to the University of Edinburgh. AMM is additionally supported by the MRC (MC_PC_17209, MC_PC_MR/R01910X/1, MR/S035818/1), The Wellcome Trust (216767/Z/19/Z ), The Sackler Trust, and has previously received research funding from Pfizer, Eli Lilly, and Janssen. Both AMM and IJD are members of The University of Edinburgh Centre for Cognitive Ageing and Cognitive Epidemiology, part of the cross council Lifelong Health and Wellbeing Initiative (MR/K026992/1); funding from the BBSRC and MRC is gratefully acknowledged. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscriptPeer reviewedPublisher PD

T₁ mapping for assessment of myocardial injury and microvascular obstruction at one week post myocardial infarction

OBJECTIVES: To compare 3T T1 mapping to conventional T2-weighted (T2W) imaging for delineating myocardial oedema one week after ST-elevation myocardial infarction (STEMI), and to explore the confounding effects of microvascular obstruction (MVO) on each technique.  METHODS: T2W spectral attenuated inversion recovery and native T1 mapping were applied in 10 healthy volunteers and 62 STEMI patients, and late gadolinium enhancement was included for infarct localisation at 1 week and at 6 months post-STEMI. Segmental T1 values and T2W signal intensity ratios were calculated; oedema volumes and salvage indices were determined in patients using image thresholding-a receiver operator characteristic (ROC) derived T1 threshold, and a 2SD T2W threshold; and the results were compared between patients with/without MVO (n=35/27).  RESULTS: Native T1 mapping delineated oedema with significantly better discriminatory power than T2W-as indicated by ROC analysis (area-under-the-curve, AUC=0.89 versus 0.83, p=0.009; and sensitivity/specificity=83/83% versus 73/73%). The optimal ROC threshold derived for T1 mapping was 1241ms, which gave significantly larger oedema volumes than 2SD T2W (p=0.006); with this threshold, patients with and without MVO showed similar oedema volumes, but patients with MVO had significantly poorer salvage indices (p<0.05) than those without. Neither method was significantly affected by MVO, the volume of which was seen to increase exponentially with infarct size.  CONCLUSIONS: Native T1 mapping at 3T can delineate oedema one week post-STEMI, showing larger oedema volumes and better discriminatory power than T2W imaging, and it is suitable for quantitative thresholding. Both techniques are robust against MVO-related magnetic susceptibility

Effects of antiplatelet therapy on stroke risk by brain imaging features of intracerebral haemorrhage and cerebral small vessel diseases: subgroup analyses of the RESTART randomised, open-label trial

Background Findings from the RESTART trial suggest that starting antiplatelet therapy might reduce the risk of recurrent symptomatic intracerebral haemorrhage compared with avoiding antiplatelet therapy. Brain imaging features of intracerebral haemorrhage and cerebral small vessel diseases (such as cerebral microbleeds) are associated with greater risks of recurrent intracerebral haemorrhage. We did subgroup analyses of the RESTART trial to explore whether these brain imaging features modify the effects of antiplatelet therapy